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1. Introduction 
ICH Q6B is a useful guide for determining appropriate analytical testing of a biotherapeutic. 
This document describes an approach to streamlining this testing by selecting a short list of 
the most powerful analytical methods early in development and the use of universal 
methods. Universal methods are designed to provide useful data for the majority of protein 
therapeutics. Some of these universal methods include size exclusion chromatography for 
the determination of aggregation and degradation products, ion exchange HPLC for the 
determination of charge variants and oligosaccharide profiling for glycosylated 
therapeutics. This allows for more testing earlier without spending time and money 
optimizing methods for a particular drug. 
The authors discuss how to determine what testing is required in early development, how 
to know when more testing is required and when more optimization of the universal 
methods is warranted. Data will be shown to demonstrate how the same assay can be 
used from initial lot-to-lot comparisons through assay validation and a full 
characterization of the therapeutic. For example, N-linked oligosaccharide profiling by 
HPLC is a relatively quick and simple means of evaluating the glycosylation of a 
biotherapeutic using chromatographic peak areas. Understanding the heterogeneity of the 
glycosylation early in product development from lot –to- lot comparisons, along with 
bioassay, in vivo and pre-clinical testing, is an effective way of defining the window for 
the product’s critical quality attributes. Further along in development, the N-linked 
profiling assay can be used to quantitate the heterogeneity of the glycosylation and the 
oligosaccharide peaks can then be collected and identified by mass spectrometry, 
glycosidase sequencing and other methods. 
2. Guiding principles for characterization throughout drug development 
The methods will change, assays may be added, and some assays eliminated during product 
development. However, as a drug moves from Pre-Clinical to Clinical to Marketing 
Approval there are certain points to keep in mind starting with the earliest lot to ensure a 
solid characterization package for your drug. 
Scientific Literature: For many drugs there is very little information on how the structure of 
the molecule impacts the function of the molecule. However, when there is information on 
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the molecule or similar molecules, this information can be used to select the quality 
attributes of your molecule most likely to affect the efficacy or safety of your drug. These 
attributes are worth monitoring over the course of development so that they can be used to 
define the design space for your drug—variation that is acceptable because it has been 
demonstrated to have no affect on the safety and efficacy of the drug.  
Retains: Assays evolve and new ones may be developed throughout the characterization 
process. It is important to be able to retrospectively analyze your drug. This is especially 
true for any clinical or key pre-clinical lots. The more lots you have to test, the easier it is to 
confidently set assay specifications.  
Reference Material: Beyond retains, it is important to establish Reference Materials. These 
are drug lots that are set aside to demonstrate that future lots are comparable to previous 
material and that the drug is not changing. These can also ensure that an assay is delivering 
consistent results over time. 
Stability: Drug lots that are not comparable to historical lots, whether these changes are 
coincident with decreased biological activity or not, are extremely valuable for 
understanding the relationship between activity and drug heterogeneity—what 
heterogeneity is acceptable and what heterogeneity negatively impacts the safety and/or 
efficacy of the drug product. It is important to identify assays that detect these critical 
quality attributes and the early in development. When changes in the product do not occur 
naturally, it is possible to force these changes using accelerated stability/degradation 
studies where the drug is stressed and forced to degrade. 
Release Tests/Assay Validation:  
It is always important to keep in mind that some assays will become Release Tests and will 
need to be validated. It is wise to remember this when choosing and designing assays to 
avoid trouble in the future when they need to be validated and transferred to a QC 
laboratory. 
3. Pre-clinical evaluation of sample heterogeneity 
Numerous lots of drug are prepared throughout development of a therapeutic. These are 
first used in animal studies, followed by preclinical studies and finally clinical studies. 
Throughout the course of these studies, valuable information regarding the heterogeneity of 
the drug can be determined early on using some basic analytical assays. These studies can 
help to define a window of acceptable product variation. “If a consistent pattern of product 
heterogeneity is demonstrated, an evaluation of the activity, efficacy, and safety (including 
immunogenicity) of individual forms may not be necessary” (ICHQ6B). For example, 
oligosaccharide profiling, IEX-HPLC and SEC-HPLC are universal assays usually requiring 
little methods development and are relatively quick and easy to perform. These assays are 
also easily transferred to a QC environment, can be validated and used as lot release assays. 
Performing these assays early in the development process helps to identify the extent of 
heterogeneity routinely seen in a sample. Performed routinely, these assays can identify 
stability issues (oxidation/deamidation or aggregation/degradation during storage) or 
critical process parameters (glycosylation changes with process change). Understanding the 
product variants at an early stage aids in optimizing the types of assays required for the 
determination of product identity later on in development. For example, if charge variants 
are present in a sample, the IEX-HPLC assay may need to be further optimized for 
resolution of these variants. Further, these variants can be isolated and subjected to peptide 
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mapping techniques so that the site of oxidation can be determined and the peptide map 
optimized to resolve the variant peptides. It is often possible to force degradation of the 
drug using accelerated stability or degradation pathway studies where the drug is stressed 
by changing parameters such as the pH of the formulation and storage temperature. This 
helps to identify critical quality attributes of the drug and determine whether the assays are 
able to detect these critical changes. It also allows for determining which changes in the 
drug impact the biological activity.  
During early stage development, there should be an adequate focus placed on determining the 
appropriate analytical tests for the identity, purity and concentration or activity of the drug.  
4. Phase I: Determination of physicochemical properties 
Determination of the physicochemical properties of the drug substance is a critical step in 
the development of suitable identity tests. These properties include the purity, concentration 
and/or activity, molecular weight and size of the sample as well as charge, hydrophobicity 
and post-translational modifications (PTMs).  
4.1 Purity and molecular weight determination 
Purity and molecular weight analyses are most easily evaluated by SDS-PAGE/CE-SDS 
(native and denaturing) along with Western blot analysis. SDS-PAGE/CE-SDS allows for 
the visualization of the protein species in a sample and can be quantitative depending on the 
detection method. Comparison of native versus denatured sample by gel electrophoresis or 
CE analysis can also confirm the presence of 3-dimensional structure such as disulfide 
bonding and oligomerization. Further analysis of the gel by Western blotting with various 
antibodies identifies the presence of drug substance degradation products along with 
process specific contaminants. If molecular weight variants such as aggregates or 
degradation products occur in a product, size exclusion chromatography can be a valuable 
tool for the routine detection and quantitation of these variants. SEC-HPLC is a universal 
method and can be run with minimal development work. SEC columns can separate over a 
wide range of molecular weights, and optimization of the column conditions need not take 
place until later in the product development stage if the method is not separating molecular 
weight variants identified in the product through orthogonal methods. SEC-HPLC can be 
preparative and used as an initial step for a two-dimensional analysis of size variants. The 
variant peaks can be isolated for characterization by MALDI-TOF MS to confirm the size or 
analyzed by peptide mapping for identity, etc. Once the purity of the sample is ascertained 
by these methods, the molecular weight of the drug substance should be confirmed by 
MALDI-TOF analysis. This type of multidimensional analysis is illustrated in work by Kotia 
et al. (Kotia, 2010). In this work, truncated fragments of a monoclonal antibody heavy and 
light chain are detected by CE-SDS. These truncated fragments were correlated to heavy and 
light chain peptide maps and sequence identity was confirmation by N-terminal sequencing. 
Multidimensional analysis of product degradation utilizing both SEC-HPLC and CEX-
HPLC followed peptide mapping with MS-ESI detection is shown in work by Lau et al. and 
Kim et al. (Lau H., 2010) (Kim, 2010) 
4.2 Protein content and extinction coefficient determination 
Protein content needs to be determined early in development since many other assays are 
dependent upon it. It is important to use an assay that is precise, i.e. gives reproducible 
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results. For instance, the results of potency and bioassays are reported based on protein 
concentration. Reporting these results based on inconsistent protein determinations yields 
inconsistent results that may not accurately reflect the activity of the drug. Determination of 
protein content is not as straightforward as it would seem. Colorimetric assays such as the 
Bradford assay or bicinchoninic acid assay rely on the use of an external reference standard 
for protein determination. However, different proteins will have different molar ratios of 
reactive sites and the same amount of one protein can give a different absorbance than the 
same amount of the reference standard used. Amino acid analysis can also be used for 
quantitative analysis of protein content, but this assay also has its difficulties. Different 
proteins can hydrolyze differently under the same conditions and many amino acids are not 
stable to acid hydrolysis. Numerous studies have been conducted by the ABRF to determine 
the precision and accuracy of colorimetric protein assays and quantitative amino acid 
analysis. These studies report high variability between test sites and variability in the 
accuracy of measuring different proteins as well. Summarizing the results from the 
AARG2003 study (Alterman et al.), 28 laboratories were given five protein samples at a 
concentration of 2.5 mg/mL. Excluding the results from the fetuin sample (average 
determined concentration = 1.18 mg/mL) the average yield of all four proteins was 1.69 ± 
0.24 mg/mL. This indicates a substantial bias (32%) in the determination of protein content, 
although some of this bias could be due to initial sample handling and salt content. In our 
hands, we see an assay bias of 13% for our BSA standard (N= 94) with an average yield of 
1.75 ± 0.47 mg/mL from a 2.01 mg/mL standard solution.  
Theoretical extinction coefficients can be easily determined from the amino acid sequence 
(e.g. using the ProtParam tool at www.ExPaSy.org). However, the extinction coefficient 
needs to be confirmed experimentally using a suitably determined protein concentration as 
protein conformation can have an effect on the measured absorbance.  
4.3 Charge and hydrophobicity variants 
Charge and hydrophobicity variants are most easily analyzed by ion-exchange and 
reversed-phase HPLC. These assays are highly sensitive and selective, both being able to 
detect changes at a single site in the protein sequence. Both assays are an excellent starting 
point for multi-dimensional analysis as the methods are quantitative and scalable. Variant 
peaks can be isolated for characterization by mass spectrometry methods or peptide 
mapping. Hydrophobicity variants can consist of single point amino acid substitutions. 
Charge variants can include oxidized, deamidated, phosphorylated, and sulfated species as 
well as variation in the extent of sialylation. More than likely these variants will need to be 
characterized using in-depth identity tests. 
Ion exchange chromatography can easily pick up low levels of charge variants. The assay is 
very quick and in general, requires only a small amount of purified protein. Running this 
analysis early on allows for the early identification of charge variants. Early identification of 
the extent, or percent modification, can be used to set product specifications. These assays can 
also be used throughout process development to determine which process changes affect 
product variation. Ion exchange HPLC is an excellent starting point for further investigation 
into the identification of the variants. Vlasek et al. describe the use of cation exchange 
chromatography for characterization of a monoclonal antibody in which two lysine variants 
were separated using CEX-HPLC as well as two acidic variants.  (Vlasak, 2009). The initial use 
of ion-exchange HPLC allowed for isolation and extensive characterization of the variant 
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peaks, such as preparation of Fab fragments from the variants as well as preparation of heavy 
and light chains, followed by mass spectrometry analysis, Edman degradation, DSC to 
evaluate stability and CD spectroscopy for higher order structure analysis. 
4.4 Glycosylation 
Glycosylation of biotherapeutics is now routinely analyzed early in development and 
typically drug lots are assayed as they are manufactured for lot-to-lot consistency in their 
glycosylation. We have already covered this topic in detail in a review article (Higgins, 
2010). Although monosaccharide composition analysis was historically used to monitor 
glycosylation (releasing monosaccharides from oligosaccharides using acid and then 
quantifying each monosaccharide) this method has now been mostly replaced by 
oligosaccharide profiling. Oligosaccharide profiling involves releasing intact N- and/or O-
linked oligosaccharides from the protein and then analyzing them by HPLC or mass 
spectrometry. Oligosaccharide profiling can be used to monitor the population of 
oligosaccharides present on the glycoprotein and most importantly determine whether the 
heterogeneity is the same from lot-to-lot. Mass spectrometry of the released pool of 
oligosaccharides can be used to characterize the types of oligosaccharides present 
(oligomannose, complex, and antennarity). Both HPLC and MS can be used to quantify the 
relative ratio of different oligosaccharides, however, MS often requires the use of radioactive 
labels. The ratio is valuable when these methods are used for lot release. 
Monosaccharide composition analysis is now mostly utilized in situations where additional 
testing is warranted: process qualification lots, lots for reference material or comparability 
testing. It is also used when a particular monosaccharide is critical to a drug (e.g. the 
amount of fucose) or could impact safety (a monosaccharide not commonly found on 
human proteins but found in the expression system used to produce the drug). Sialic acid 
analysis can also be a useful assay since the level of sialylation is often a critical quality 
attribute as it affects the plasma clearance of many glycoproteins.  
5. Phase II/III: Development and characterization of identity tests 
5.1 Determination of primary amino acid sequence and peptide mapping 
The primary amino acid sequence of a protein is determined using a combination of 
analytical techniques. Complete sequence information is often difficult to obtain. The N and 
C terminal amino acids need to be confirmed. N-terminal sequencing can be performed by 
Edman degradation or MALDI-PSD analysis. MALDI-PSD analysis has the advantage in 
that it can also be used to identify the C-terminal amino acids in a protein or a peptide. 
Otherwise, C-terminal sequencing involves the use of a specific C-terminal protease 
followed by separation and identification of the released amino acids by HPLC. Full 
sequence determination is generally performed using a combination of peptide mapping 
following peak identification by Edman degradation or MS/MS. 
Development of a good peptide map is critical for the development of appropriate identity 
tests. Once the purity of the product has been established the identity of the protein should 
be determined by peptide mapping. Peptide mapping involves cleaving a protein into 
smaller peptides, generally using enzymes that cleave the protein at specific amino acids to 
generate peptides that can be predicted from the peptide sequence. These peptides are then 
separated by reversed-phase HPLC followed by detection using UV and/or MS. At the start, 
if the protein is known to contain N-linked oligosaccharides or disulfide bonds, comparative 
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peptide maps of deglycosylated and non-reduced protein should be generated to evaluate 
the extent of variability in these regions and to begin identifying the disulfide linked 
peptides and the glycopeptides. A good peptide map will resolve most of the peptides in the 
mixture to baseline. Well resolved peaks can then be identified by N-terminal sequencing 
using Edman degradation or LC-MS. Both methods are commonly used. 
5.2 Disulfide and glycopeptide mapping 
If a protein contains disulfide bonds, it is necessary to cleave the disulfide bond with a 
suitable reducing agent such as dithiothreitol followed by blockage of the free cysteine with 
an agent such as iodoacetamide or iodoacetic acid to prevent the random reformation of the 
bonds. Reduction of the disulfide bonds is necessary to confirm the amino acid sequence of 
the peptide, as mixed peptides will not correlate to the known amino acid sequence. 
Peptides involved in disulfide linkages can be identified by comparison of the reduced and 
alkylated peptide map with a peptide map generated from the non-reduced protein (see 
Figure 1). Additional identification of the peptides involved in the disulfide bridging can be 
confirmed by MALDI-TOF analysis using a reducing matrix. These matrices will break the 
disulfide bonds on target, generating masses of the disulfide linked peptide along with the 
masses of each of the released peptides. Examples of the peptide mapping for the 
determination of disulfide bonding in antibodies can be found in Bloom (1997) and Wypych 
(2008)(Bloom, 1997). 
 
 
Fig. 1. Disulfide Peptide Map of Fetuin. The tryptic peptide map is enlarged to show the 
region of the map containing the most changes. Arrows indicate the generation of new 
peaks in the peptide map when fetuin is reduced and alkylated prior to trypsin digest. The 
top (red) chromatogram represents fetuin tryptic peptides generated from non-reduced 
fetuin. The bottom (black) chromatogram represents fetuin tryptic peptides generated from 
reduced and alkylated fetuin. 
Comparison of peptide maps generated from glycosylated and deglycosylated drug substance 
can be used to identify glycosylated peptides (see Figure 2). Identification of these peptides can 
be performed by LC-MS, LC-MALDI or N-terminal sequencing. Further, glycosylated peaks 
can be isolated and for the purpose of attempting to determine the type of glycosylation on the 
peptide. Examples of approaches to the identification of glycopeptides by glycopeptide 
mapping can be found in (Rohrer, 1993) (Ohta, 2002)Ohta (2002) and Rohrer (1993). 
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Fig. 2. Glycopeptide Map of Fetuin. The tryptic peptide map is enlarged to show the region 
of the map containing the most changes. The top (black) chromatogram represents fetuin 
peptides deglycosylated using PNGase F prior to reversed-phase chromatography. The 
bottom (red) chromatogram represents the same, untreated tryptic peptides. Arrows 
indicate the deglycosylated glycopeptides. 
5.3 Site-specific glycosylation 
Site-specific glycosylation analysis gives detailed data on the relationship between peptide 
and glycosylation heterogeneity. A review by An et al (2009) describes current methods 
used. The most challenging part of site-specific analysis is the enrichment of glycopeptides, 
a necessary step due to the relative low abundance of glycopeptides in comparison to non-
glycosylated peptides. Such methods as lectin affinity columns, HILIC (Hydrophilic 
Interaction Chromatography) or ERLIC (Electrostatic Repulsion-Hydrophilic Interaction 
Chromatography) columns are employed, to varying degrees of success. 
Lectins will bind oligosaccharides and different lectins show a preference for different types 
of oligosaccharides. Lectin affinity columns can therefore be used to bind glycopeptides 
and/or separate glycopeptides into groups with differences in their oligosaccharides. HILIC 
enrichment is based upon the proposed increase in hydrophilicity of glycopeptides versus 
non-glycosylated peptides due to the polysaccharide moiety. ERLIC operates in a similar 
fashion as HILIC, with the addition of electrostatic interactions to the binding mechanism. 
Both HILIC and ERLIC utilize gradients of high organic solvent to low organic solvent, 
where HILIC is generally performed using a polar chromatographic matrix and ERLIC 
utilizing an ion exchange matrix. Glycopeptides will bind more strongly than most non-
glycosylated peptides, allowing for the removal of non-glycosylated peptides from a 
mixture. While these methods can enrich the glycopeptide content of a peptide mixture, the 
separation of the two has not been optimized. Some glycopeptides will be found in the early 
eluting fractions, and complex mixtures of glycopeptides can be seen to elute over a wide 
concentration of decreasing organic solvent along with some non-glycosylated peptides. 
Due to the heterogeneous nature of glycosylation, one peptide might contain many different 
glycoforms, leading to challenges in separation and identification.  
5.4 Characterization of the oligosaccharide profile 
Characterization of the oligosaccharide profile is critical for understanding the heterogeneity 
of glycosylation. By having a well-characterized oligosaccharide profile, changes in 
glycosylation are easier to track. A summary of characterization options is shown in Figure 
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3. Oligosaccharide profiling is commonly done by HPLC coupled with fluorescent detection 
(after oligosaccharide derivatization with a fluorescent label such as 2-aminobenzoic acid or 
2-aminobenzamide), in-line LC-MS (typically using electrospray ionization (ESI) as the MS 
ion source) or standalone MS (either permethylated, derivatized, or native glycans using 
either MALDI or ESI).  
 
 
Fig. 3. A flowchart of possible approaches for characterization of the oligosaccharide profile.  
When working from an HPLC fluorescent profiling method, fractions must be collected for 
further characterization. After fractions are collected, glycoforms can be identified either 
through glycosidase sequencing, which relies on highly specific enzymes and shifts in 
retention times to confirm linkage and composition, or through further mass spectrometric 
analysis. An example of HPLC profile characterization of the N- and O-linked 
oligosaccharides of fetuin using fraction collection followed by MALDI-TOF-MS 
identification is shown in Figure 4. Additional mass spectrometric analysis may include post 
source decay using MALDI-TOF-MS, MSn using such fragmentation techniques as electron 
transfer dissociation (ETD) or collision induced dissociation (CID), or glycosidase 
sequencing using shifts in mass to identify losses from the parent mass. A review by Geyer 
and Geyer (2006) contains further information. Often, multiple approaches are needed to 
fully characterize an oligosaccharide profile, as seen in Qian et al (2006).  
While MS-MS and MSn are powerful tools, analysis of mass spectrometric data can be 
complicated and time-consuming, requiring database searches and knowledge of 
glycobiology to successfully narrow down potential structures. While several groups have 
sought to automate the process, in the authors’ experience the results often contain 
inaccurate structures, not likely to be found in nature, which makes data analysis more 
complex. 
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Fig. 4. N- and O-linked Oligosaccharide Profile of Fetuin. The selected fractions were 
collected and analyzed by negative ion mode MALDI-TOF-MS to determine peak identity. 
Linkages were not confirmed; however, the results are strongly correlated to the literature 
on fetuin. Symbols:  N-acetylglucosamine (GlcNAc);  N-acetylgalactosamine (GalNAc); 
 galactose;  mannose,  fucose and ♦ sialic acid. 
6. Marketing approval: Lot release assays 
Many assays can be used to characterize a drug during development. Some will continue to 
be used to trouble shoot production problems and demonstrate comparability through 
process changes and a subset of these assays will become release assays. The list will include 
release assays common to most, if not all, biotherapeutics such as concentration, purity, 
peptide mapping and oligosaccharide profiling. Additionally, any assays determined during 
process development which monitor critical quality attributes specific to the drug will 
become a release assay. These assays could include quantification of sialic acid, assays used 
to evaluate the truncation of the amino acid sequence and assays which identify post-
translational medications such as phosphorylation or gamma carboxylation. 
Unlike assays used for characterization, the release assays will need to be validated and 
transferred to QC laboratories. Some of these assays such as concentration or activity are so 
important for moving the product into the clinic that they will need to be validated early 
and used for lot release on earlier lots. Other assays, like peptide mapping and 
oligosaccharide profiling might not be validated until later (but before marketing approval). 
This allows more time for the extensive work often required to identify the 
peptides/oligosaccharides in the peaks and collect data on any variation seen in these 
separations from many drug lots before setting specifications. 
7. Conclusions 
An approach to characterization of a therapeutic has been presented in which analytical 
testing is simplified by initially focusing on the assays required early in development for all 
therapeutics (purity, molecular weight, activity and/or concentration). Next, the drug is 
evaluated using assays that are routinely used for release testing such as peptide mapping 
and oligosaccharide profiling. Incorporating these assays earlier in development allows for 
better tracking of lot-to-lot variation in the product and collection of more data before 
setting assay specifications. Finally, assays will need to be added or existing assays 
modified, to track variation in the drug that is detected during development (changes such 
as truncation of the protein or post-translational modifications). Tracking any heterogeneity 
in the drug is most critical if it is likely to affect the safety or efficacy of the drug. 
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The authors believe that it is important to use universal methods. Universal methods do not 
require extensive assay development work and are sensitive to certain physicochemical 
properties of the drug such as molecular weight or charge. It is better to obtain more data 
earlier in development using these universal methods than to spend time early in drug 
development optimizing assays specific for your protein before understanding the 
heterogeneity naturally present in your drug and how it is likely to degrade. 
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